My High-risk Flu Patients Get Antibiotics, and Here’s Why

Evolocumab significantly reduced major cardiovascular events in high-risk patients without prior heart attack or stroke, making it the first PCSK9 inhibitor with proven benefit in both primary and secondary prevention.

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.

PODCAST: Family physician Ada Stewart, MD, shares practical strategies for cervical cancer screening and patient communication.

This year, the FMX Main Stage presenters will be led by Vivek H Murthy, the 21st US Surgeon General. Learn more about him and the 2 other inspiring guests.

The FDA has granted fast track designation to BMS-986446, an anti–microtubule binding region tau antibody in phase 2 trials for early Alzheimer disease.